gdc-0973 has been researched along with Stevens-Johnson-Syndrome* in 2 studies
2 other study(ies) available for gdc-0973 and Stevens-Johnson-Syndrome
| Article | Year |
|---|---|
Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.
Topics: Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Humans; Melanoma; Piperidines; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Stevens-Johnson Syndrome; Vemurafenib | 2022 |
Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.
Combination therapy in the treatment of metastatic melanoma has been associated with more durable response rate compared to monotherapy. However, previous studies have shown that combined target therapy commonly causes a wide spectrum of adverse events. These adverse reactions are usually manageable, however, it is always necessary to compare drug efficacy with its potential adverse effects. Toxic epidermal necrolysis represents severe mucocutaneous reaction, usually triggered by medications and characterized by extensive necrosis and detachment of the epidermis. Here we present a first case of toxic epidermal necrolysis induced by combined target therapy (vemurafenib plus cobimetinib). The case was observed in a young patient with BRAF mutant melanoma who was started on first-line metastatic immunotherapy with pembrolisumab. Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Humans; Male; Melanoma; Piperidines; Proto-Oncogene Proteins B-raf; Stevens-Johnson Syndrome; Vemurafenib | 2020 |